Product Partnering Opportunities
Adding ValueArana has several compounds available for partnering and out-licensing.
ART621 is a domain antibody based therapeutic developed through Arana’s collaboration with Domantis. The compound completed Phase I clinical trials in October 2007 and is scheduled for Phase II studies in early 2008. This compound offers a unique opportunity for companies wishing to participate in a rapidly expanding market (revenues for TNF biologics in 2006 were in excess of US$10 billion) in a number of indications, including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis and psoriatic arthritis.
PMX53 is our lead peptide derivative which inhibits inflammation by targeting the human C5a ‘complement’ factor receptor – a new approach that is widely regarded in the field as offering significant opportunity for new treatments in inflammatory diseases including psoriasis, age related macular degeneration (AMD) and other diseases of the eye. Arana is in the process of optimising new formulations as well as undertaking pre-clinical validation in several inflammatory models. A new formulation will be taken into a Phase trial to supplement the clinical data obtained by Promics Ltd., acquired by Arana in 2006.
ART104 is amonoclonal antibody with demonstrated direct cancer cell killing properties. This product is undergoing the final stage of lead optimisation and will be developed initially for the treatment of colorectal cancers and has potential for additional indications.
ART010 is an osteoprotegerin variant protein which inhibits the RANK/RANKL interaction, and has been shown in cell-based testing to retain little, if any, TRAIL inhibiting activity, while preserving the full ability of Osteoprotegerin to reduce bone loss. The lead indication will be the treatment of bone metastasis and initial clinical studies are scheduled to commence early 2009.
If you would like to enter into partnering discussions with Arana Therapeutics please contact: -
Cliff Holloway Ph.D,
Vice President, Business Development
partnering@arana.com